(SLDB) Solid Biosciences - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 637m USD | Total Return: 129.1% in 12m
Avg Turnover: 7.33M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Share dilution 65.5% YoY
Interest Coverage Ratio -484.6 is critical
Altman Z'' -15.00 < 1.0 - financial distress zone
Volatile Below Avwap Earnings
Tailwinds
No distinct edge detected
Solid Biosciences Inc. (SLDB) is a clinical-stage biotechnology company focused on developing gene therapies for rare neuromuscular and cardiac disorders. Its pipeline is led by SGT-003, a candidate for Duchenne muscular dystrophy currently in Phase 1/2 clinical trials, alongside several preclinical programs targeting Friedreichs ataxia and various forms of dilated cardiomyopathy.
The company operates within the high-risk, high-reward gene therapy sector, where business models typically rely on securing intellectual property through academic partnerships and advancing proprietary delivery platforms. Solid Biosciences utilizes a specialized technology stack including synthetic capsids and genetic regulators to improve the precision and expression of its therapeutic payloads.
Investors can find further data and trend analysis for this ticker on ValueRay.
Strategic collaborations with entities such as Ultragenyx Pharmaceutical and multiple research universities provide the framework for its manufacturing and clinical development. Headquartered in Massachusetts, the firm continues to expand its platform technologies to address unmet needs in rare genetic diseases.
- SGT-003 clinical trial data readouts drive near-term valuation for Duchenne pipeline
- FDA regulatory milestones for gene therapy platforms dictate long-term market entry
- R&D expenditure levels and cash runway sustain preclinical cardiac program development
- Strategic partnerships with Ultragenyx provide essential capital and manufacturing validation
- Competitive landscape in neuromuscular gene therapy impacts market share and pricing power
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.41 > 0.02 and ΔFCF/TA -9.67 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.41 > 3% & CFO -171.7m > Net Income -191.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 13.10 > 1.5 & < 3 |
| Outstanding Shares: last quarter (109.8m) vs 12m ago 65.53% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.91%; Δ -0.91% > 0%) |
| Interest Coverage Ratio: -484.6 > 6 (EBITDA TTM -190.3m / Interest Expense TTM 396k) |
| A: 0.87 (Total Current Assets 396.8m - Total Current Liabilities 30.3m) / Total Assets 422.9m |
| B: -2.40 (Retained Earnings -1.01b / Total Assets 422.9m) |
| C: -0.50 (EBIT TTM -191.9m / Avg Total Assets 383.4m) |
| D: -20.80 (Book Value of Equity -1.01b / Total Liabilities 48.8m) |
| Altman-Z'' = -27.34 = D |
As of May 24, 2026, the stock is trading at USD 6.50 with a total of 742,801 shares traded.
Over the past week, the price has changed by -4.34%,
over one month by -21.19%,
over three months by +12.78% and
over the past year by +129.07%.
Solid Biosciences has received a consensus analysts rating of 4.58. Therefore, it is recommended to buy SLDB.
- StrongBuy: 7
- Buy: 5
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 17 | 161.5% |
P/B = 1.6025
Revenue TTM = 0.0 USD
EBIT TTM = -191.9m USD
EBITDA TTM = -190.3m USD
Long Term Debt = 18.5m USD (estimated: total debt 20.7m - short term 2.19m)
Short Term Debt = 2.19m USD (from shortTermDebt, last quarter)
Debt = 20.7m USD (from shortLongTermDebtTotal, last quarter) (leases 20.7m already included)
Net Debt = -360.7m USD (calculated: Debt 20.7m - CCE 381.3m)
Enterprise Value = 276.3m USD (637.0m + Debt 20.7m - CCE 381.3m)
Interest Coverage Ratio = -484.6 (Ebit TTM -191.9m / Interest Expense TTM 396k)
EV/FCF = -1.60x (Enterprise Value 276.3m / FCF TTM -172.9m)
FCF Yield = -62.56% (FCF TTM -172.9m / Enterprise Value 276.3m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 1.62m) / Revenue TTM)
Tobins Q-Ratio = 0.65 (Enterprise Value 276.3m / Total Assets 422.9m)
Interest Expense / Debt = 1.92% (Interest Expense 396k / Debt 20.7m)
Taxrate = 21.0% (US default 21%)
NOPAT = -151.6m (EBIT -191.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 13.10 (Total Current Assets 396.8m / Total Current Liabilities 30.3m)
Debt / Equity = 0.06 (Debt 20.7m / totalStockholderEquity, last quarter 374.1m)
Debt / EBITDA = 1.90 (negative EBITDA) (Net Debt -360.7m / EBITDA -190.3m)
Debt / FCF = 2.09 (negative FCF - burning cash) (Net Debt -360.7m / FCF TTM -172.9m)
Total Stockholder Equity = 257.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -50.02% (Net Income -191.8m / Total Assets 422.9m)
RoE = -15.08% (Net Income TTM -191.8m / Total Stockholder Equity 1.27b)
RoCE = -14.87% (EBIT -191.9m / Capital Employed (Equity 1.27b + L.T.Debt 18.5m))
RoIC = -1.12k% (out of range, set to none) (NOPAT -151.6m / Invested Capital 13.5m)
WACC = 15.23% (E(637.0m)/V(657.6m) * Re(15.68%) + D(20.7m)/V(657.6m) * Rd(1.92%) * (1-Tc(0.21)))
Discount Rate = 15.68% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 100.00 | Cagr: 80.66%
[DCF] Fair Price = unknown (Cash Flow -172.9m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.52 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.47 | Chg30d=-14.86% | Revisions=-38% | Analysts=13
EPS next Quarter (2026-09-30): EPS=-0.48 | Chg30d=-14.03% | Revisions=-38% | Analysts=13
EPS current Year (2026-12-31): EPS=-1.98 | Chg30d=-15.00% | Revisions=-57% | GrowthEPS=+0.5% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-1.93 | Chg30d=-14.39% | Revisions=-54% | GrowthEPS=+2.6% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -57%